Cogent Biosciences (COGT) Convertible Debt (2025 - 2026)
Cogent Biosciences (COGT) posted quarterly Convertible Debt of $223.2 million for Q1 2026, little changed quarter-over-quarter from $222.9 million in Q4 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Convertible Debt (2025 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Convertible Debt for 2 consecutive years, with $223.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Convertible Debt changed N/A year-over-year to $223.2 million; the TTM figure through Mar 2026 stood at $223.2 million (changed N/A YoY), while the FY2025 annual figure was $222.9 million, changed N/A from the prior year.
- Convertible Debt held at $223.2 million in Q1 2026 per COGT's latest filing, from $222.9 million in the prior quarter.
- Across five years, Convertible Debt topped out at $223.2 million in Q1 2026 and bottomed at $222.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 223.46 Mn |
| Mar 31, 2026 | 223.17 Mn |
| Dec 31, 2025 | 222.90 Mn |